Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Experimental treatment of antipsychotic-induced movement disorders.

Shireen E.

J Exp Pharmacol. 2016 Aug 8;8:1-10. doi: 10.2147/JEP.S63553. eCollection 2016. Review.

2.

Gray matter volume alterations in first-episode drug-naïve patients with deficit and nondeficit schizophrenia.

Lei W, Deng W, Li M, He Z, Han Y, Huang C, Ma X, Wang Q, Guo W, Li Y, Jiang L, Gong Q, Hu X, Zhang N, Li T.

Psychiatry Res. 2015 Nov 30;234(2):219-26. doi: 10.1016/j.pscychresns.2015.09.015. Epub 2015 Sep 11.

3.

Selective Estrogen Receptor Modulation Increases Hippocampal Activity during Probabilistic Association Learning in Schizophrenia.

Kindler J, Weickert CS, Skilleter AJ, Catts SV, Lenroot R, Weickert TW.

Neuropsychopharmacology. 2015 Sep;40(10):2388-97. doi: 10.1038/npp.2015.88. Epub 2015 Apr 1.

4.

Peripheral BDNF: a candidate biomarker of healthy neural activity during learning is disrupted in schizophrenia.

Skilleter AJ, Weickert CS, Vercammen A, Lenroot R, Weickert TW.

Psychol Med. 2015 Mar;45(4):841-54. doi: 10.1017/S0033291714001925. Epub 2014 Aug 27.

5.

Use of antipsychotics for the treatment of intensive care unit delirium.

Page VJ, Casarin A.

Rev Bras Ter Intensiva. 2014 Apr-Jun;26(2):86-8. English, Portuguese. No abstract available.

6.

Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.

Godman B, Petzold M, Bennett K, Bennie M, Bucsics A, Finlayson AE, Martin A, Persson M, Piessnegger J, Raschi E, Simoens S, Zara C, Barbui C.

BMC Med. 2014 Jun 13;12:98. doi: 10.1186/1741-7015-12-98.

7.

Locomotor hyperactivity in 14-3-3ζ KO mice is associated with dopamine transporter dysfunction.

Ramshaw H, Xu X, Jaehne EJ, McCarthy P, Greenberg Z, Saleh E, McClure B, Woodcock J, Kabbara S, Wiszniak S, Wang TY, Parish C, van den Buuse M, Baune BT, Lopez A, Schwarz Q.

Transl Psychiatry. 2013 Dec 3;3:e327. doi: 10.1038/tp.2013.99.

8.

Antipsychotics in children and adolescents with schizophrenia: a systematic review and meta-analysis.

Sarkar S, Grover S.

Indian J Pharmacol. 2013 Sep-Oct;45(5):439-46. doi: 10.4103/0253-7613.117720. Review.

9.

Brain levels of the neurotoxic pyridinium metabolite HPP+ and extrapyramidal symptoms in haloperidol-treated mice.

Crowley JJ, Ashraf-Khorassani M, Castagnoli N Jr, Sullivan PF.

Neurotoxicology. 2013 Dec;39:153-7. doi: 10.1016/j.neuro.2013.09.005. Epub 2013 Oct 6.

10.

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments.

Chien WT, Yip AL.

Neuropsychiatr Dis Treat. 2013;9:1311-32. doi: 10.2147/NDT.S37485. Epub 2013 Sep 11. Review.

11.

Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.

Godman B, Bucsics A, Burkhardt T, Piessnegger J, Schmitzer M, Barbui C, Raschi E, Bennie M, Gustafsson LL.

Front Pharmacol. 2013 Jan 7;3:198. doi: 10.3389/fphar.2012.00198. eCollection 2012.

12.

Challenges in validating quality of care data in a schizophrenia registry: experience from the Danish National Indicator Project.

Pedersen CG, Gradus JL, Johnsen SP, Mainz J.

Clin Epidemiol. 2012;4:201-7. doi: 10.2147/CLEP.S29419. Epub 2012 Aug 10.

13.

Lack of cortico-limbic coupling in bipolar disorder and schizophrenia during emotion regulation.

Morris RW, Sparks A, Mitchell PB, Weickert CS, Green MJ.

Transl Psychiatry. 2012 Mar 13;2:e90. doi: 10.1038/tp.2012.16.

14.

Beyond dopamine: glutamate as a target for future antipsychotics.

Sendt KV, Giaroli G, Tracy DK.

ISRN Pharmacol. 2012;2012:427267. doi: 10.5402/2012/427267. Epub 2012 Jul 5.

15.

Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU.

Schizophr Res. 2012 Jun;138(1):18-28. doi: 10.1016/j.schres.2012.03.018. Epub 2012 Apr 24. Review.

16.

Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.

Kuo CJ, Yang SY, Liao YT, Chen WJ, Lee WC, Shau WY, Chang YT, Tsai SY, Chen CC.

Schizophr Bull. 2013 May;39(3):648-57. doi: 10.1093/schbul/sbr202. Epub 2012 Jan 26.

17.

Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.

Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU.

Mol Psychiatry. 2013 Jan;18(1):53-66. doi: 10.1038/mp.2011.143. Epub 2011 Nov 29. Review.

18.

Treatment-refractory schizophrenia.

Caspi A, Davidson M, Tamminga CA.

Dialogues Clin Neurosci. 2004 Mar;6(1):61-70.

19.

Disambiguating ventral striatum fMRI-related BOLD signal during reward prediction in schizophrenia.

Morris RW, Vercammen A, Lenroot R, Moore L, Langton JM, Short B, Kulkarni J, Curtis J, O'Donnell M, Weickert CS, Weickert TW.

Mol Psychiatry. 2012 Mar;17(3):235, 280-9. doi: 10.1038/mp.2011.75. Epub 2011 Jun 28.

20.

Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia.

Phanthunane P, Vos T, Whiteford H, Bertram M.

Cost Eff Resour Alloc. 2011 May 13;9:6. doi: 10.1186/1478-7547-9-6.

Items per page

Supplemental Content

Write to the Help Desk